Calcitonin Salmon

CAS No:	47931-85-1
EINECS No:	256-342-8
Synonyms:	Salcatonin, salmon calcitonin, sCT

Product Summary

Calcitonin Salmon is a potent, bioactive peptide that regulates bone and calcium metabolism by directly inhibiting osteoclastic bone resorption and promoting renal calcium excretion. Its enhanced potency compared to human calcitonin makes it especially valuable in scientific research on bone diseases, calcium homeostasis, and endocrine disorders.

Formula: C₁₄₅H₂₄₀N₄₄O₄₈S₂
Molecular Weight: 3431.85

Biochemical Function & Mechanism of Action

Calcitonin Salmon is a synthetic peptide hormone composed of 32 amino acids that mimics the function of endogenous human calcitonin, but is significantly more potent due to species-specific receptor affinity. Calcitonin Salmon acts primarily through calcitonin receptors on osteoclasts (bone-resorbing cells), exerting the following effects:

Inhibits osteoclast activity: Reduces bone resorption and calcium release from bones.
Promotes renal excretion: Enhances excretion of calcium, phosphate, and sodium in the kidneys.
Reduces serum calcium: Through both direct bone and renal effects, thereby lowering elevated blood calcium levels.

It does not require enzymatic activation, and it functions directly by binding G-protein-coupled receptors on target cells.

Applications in Scientific Research

Osteoporosis research: Understanding antiresorptive therapies and bone turnover.
Paget’s disease models: Study of abnormal bone remodeling.
Hypercalcemia studies: Models of hormone therapy for calcium control.
Bone metastasis and cancer research: Exploring bone-protective agents.
Neuroprotection studies: Investigating roles in CNS beyond bone metabolism.

Packaging & Storage

Store at 2 to 8°C.

References

Overgaard K. 1994: Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study, Calcif Tissue Int. 55(2): 82-6.
Thamsborg G, et al. 1996: Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis, Bone. 18(2): 207-12.
Karsdal MA, et al. 2015: Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials, Osteoarthritis Cartilage. 23(4): 532-43.
Bagger YZ, et al. 2018: Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis, Bone. 37(3): 425-30.
Lipp L, et al. 2019: Controlled delivery of salmon calcitonin using thermosensitive triblock copolymer depot for treatment of osteoporosis, ACS Omega. 4(1): 1157-66.
Chen J, et al. 2025: Effect of salmon calcitonin combined with calcium antagonist on blood calcium and phosphorus ion concentration in osteoporosis rats, Eur J Med Res. 30(115).
Mystakidou K, et al. 1999: Collagen structure–function relationships from solid-state NMR spectroscopy, J Pain Symptom Manage. 18(5): 323-30.
Feigh M, et al. 2014: Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats, Eur J Pharmacol. 737: 91-6.
Wells G, et al. 2015: Does salmon calcitonin cause cancer? A review and meta-analysis, Osteoporos Int. 27: 13–9.
Jiang J, et al. 2022: Salmon calcitonin exerts an antidepressant effect by activating amylin receptors, Front Pharmacol. 3: 826055.
Plosker GL, McTavish D. 1996: Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis, Drugs Aging. 8(5): 378-400.
Chesnut CH 3rd, et al. 2023: Salmon calcitonin: a review of current and future therapeutic indications, Osteoporos Int. 19(4): 479-91.